Clinical support for PROMETHEUS® Anser® IFX and PROMETHEUS® Anser® ADA

All tests are supported with strong clinical data and published literature.

Peer-reviewed journal articles supporting monitoring of biologics

Publications and peer-reviewed articles using
PROMETHEUS Anser IFX and PROMETHEUS Anser ADA

  • Wang S-L, Ohrmund L, Hauenstein S, et al. Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum.
    J Immunol Methods. 2012;382(1-2):177-188.
    read
  • Wang S-L, Hauenstein S, Ohrmund L, et al. Monitoring of adalimumab and antibodies-to-adalimumab levels in patient serum by the homogeneous mobility shift assay. J Pharm Biomed Anal. 2013;78-79:39-44.
    read
  • Ben-Bassat O, Hauenstein S, Iacono A, Irwin SP, Singh S,
    Greenberg GR. Serum adalimumab and immunogenicity in IBD patients after 80mg biweekly maintenance therapy. Abstract presented at: Digestive Disease Week 2013; May 18-21, 2013; Orlando, FL.
  • Velayos FS, Sheibani S, Lockton S, et al. Prevalence of antibodies to adalimumab (ATA) and significance of ATA/drug concentration on CRP and symptoms in unselected IBD patients. Abstract presented at: Digestive Disease Week 2013; May 18-21, 2013; Orlando, FL.
  • Yarur A, Hauenstein S, Lockton S, Singh S, Abreu M. Serum adalimumab levels and antibodies correlate with endoscopic intestinal inflammation and inflammatory markers in patients with inflammatory bowel disease. Abstract presented at: Digestive Disease Week 2013;
    May 18-21, 2013; Orlando, FL.
  • Wolf D, Hauenstein S, Lockton S, Singh S. Mechanisms of loss of response to adalimumab in Crohn's disease. Abstract presented at: Digestive Disease Week 2013; May 18-21, 2013; Orlando, FL.
  • Novel infliximab (IFX) and antibody-to-infliximab (ATI) assays are predictive of disease activity in patients with Crohn's disease (CD). Gastroenterol Hepatol. 2012;8(7)(suppl 4):3-4.
  • Murthy S, Kevans D, Seow CH, et al. Association of serum infliximab and antibodies to infliximab to long-term clinical outcome in acute ulcerative colitis. Gastroenterology. 2012;142(5)(suppl 1):S-388.
  • Veres G, Kaplan JL, De Greef E, et al. New assay to detect infliximab levels and anti-infliximab antibodies from a single serum sample is useful in measuring efficacy of treatment with infliximab in children with IBD. Gastroenterology. 2012;142(5)(suppl 1):S-386.
  • Kevans D, Murthy S, Iacono A, Silverberg MS, Greenberg GR. Accelerated clearance of serum infliximab during induction therapy for acute ulcerative colitis is associated with treatment failure. Gastroenterology. 2012;142(5)(suppl 1):S-385.
  • Vande Casteele N, Cuypers L, Singh S, et al. Antibodies to infliximab can either be persistent or transient: a retrospective case-control study in IBD patients treated with infliximab maintenance therapy. Gastroenterology. 2012;142(5)(suppl 1):S-114.

 
©2017 Société des Produits Nestlé S.A. Vevey, Switzerland.  All rights reserved.
A Nestlé Health Science Company